MeCure Industries Plc
Every TNI analysis that covers MeCure Industries Plc.
Nigerian Pharma 9M 2026 Scorecard: May & Baker Wins on Quality, Fidson on Scale, MeCure Carries the Debt
A calmer naira and lower FX losses lifted every listed drugmaker in 2026. Only May & Baker turned that into clean, cash-backed, cheaply priced earnings.
9 November 2026 · Read analysis →MeCure 9M 2026: Operations Fire, but the Bank Takes Half
MeCure's EBIT jumped 34% to N17.5bn, but N8.8bn of finance costs, N55bn of net debt and a 28x P/E make it the sector's highest-risk growth story.
9 November 2026 · Read analysis →